Operator
Thank you for standing by, and welcome to the Autosomal Dominant Hypocalcemia Type 1 investor webinar. (Operator Instructions) I’d now like to turn the call over to Ananth Sridhar. You may begin.
Ananth sridhar
Thank you, operator, and good morning, everyone. We’re pleased to have you join us as we provide a presentation to discuss encaleret, a small molecule that we’re developing for autosomal dominant hypocalcemia type 1, abbreviated as ADH1 throughout this presentation.
On our next slide, you’ll see our forward-looking statements. This presentation will include forward-looking statements. Actual results may differ due to various factors.
On this call, I’m privileged to be joined by Dr. Rachel Gafni, a senior research physician at the NIDCR of the National Institutes of Health, will present an overview of ADH1 and of encaleret. I’m also joined by Dr. Scott Adler, the Chief Medical Officer of Calcilytix Therapeutics, the BridgeBio affiliate that is dedicated to the development of encaleret. Dr. Adler will provide a review of the encaleret clinical development program.
I will also provide our perspectives on the market opportunity for ADH1, and we will conclude the presentation with a question-and-answer session. Before I hand the call to Dr. Gafni, we wanted to illuminate the patient experience with ADH1. And by doing so, we thought the best way was to start with the video featuring Jessica, an individual living with ADH1 and her story.
GIPHY App Key not set. Please check settings